

Artificial Intelligence in Embryo Selection: A New Paradigm for Assisted Reproduction

Sedigheh Ekraminasab

Department of Hematology and Blood Banking, School of
Allied Medical Sciences, Shahid Beheshti University of
Medical Sciences, Tehran, Iran
Email: s.ekraminasab@gmail.com

Abstract

Background: Embryo selection is critical to IVF success. Traditional morphological assessment is limited by subjectivity. AI and deep learning offer a paradigm shift towards objective, data-driven embryo viability analysis.

Objective: To provide a critical synthesis of the application of Artificial Intelligence (AI) in embryo selection for in vitro fertilization (IVF), focusing on its evolution, clinical evidence, and implementation challenges.

Methods: A narrative review and critical appraisal of the literature was conducted, examining the technological foundations of AI, its comparative performance against embryologists, and the transition from retrospective validation to prospective clinical trials.

Results: AI models demonstrate superior or non-inferior performance compared to embryologists in predicting key developmental outcomes. Major challenges to clinical adoption include the "black box" problem, data bias affecting generalizability, and evolving regulatory frameworks. The role of the embryologist is consequently evolving towards that of an AI-augmented curator.

Conclusion: AI is a validated and transformative tool in modern embryology. Its responsible integration into mainstream IVF practice requires robust clinical validation through multi-center trials, the development of explainable AI, and clear ethical guidelines to ensure it augments clinical expertise.

Keywords: Artificial Intelligence, Deep Learning, Embryo Selection, In Vitro Fertilization, Time-Lapse Imaging, Convolutional Neural Networks

I. INTRODUCTION

The primary objective of in vitro fertilization (IVF) is the birth of a healthy singleton infant. Central to this goal is selecting the single embryo with the highest intrinsic potential for implantation and live birth. (1) For decades, selection has relied on visual assessment of embryonic morphology—from static grading systems to dynamic time-lapse microscopy (TLM) evaluating morphokinetic parameters. (2, 3) However, these conventional methods face inherent limitations. Static morphology is vulnerable to inter-observer variability, while TLM's manual annotation of morphokinetic timings remains subjective. (4) Large randomized trials have questioned TLM's added value for predicting live birth over standard morphology. (5) Crucially, both approaches depend on human experts identifying predefined features, potentially overlooking subtle, complex patterns determinative of embryonic fate. (6) Artificial Intelligence (AI), particularly deep learning (DL), emerges as a disruptive solution. DL algorithms, such as convolutional neural networks (CNNs), autonomously learn discriminative features directly from raw embryo images or videos, bypassing human bias. (7) This enables holistic analysis of nuanced morphological textures and dynamic temporal patterns. Early proof-of-concept studies demonstrate AI models can predict blastocyst formation and outperform embryologists in ranking embryos for implantation likelihood. (8) Nevertheless, AI's transition from research tool to clinical cornerstone faces significant hurdles. The "black box" nature of complex DL models raises concerns regarding interpretability and trust. Performance in retrospective, single-center studies does not guarantee generalizability across diverse populations and laboratory protocols. (9) Ultimately, efficacy must be proven through rigorous, multicenter randomized controlled trials (RCTs) with live birth endpoints. (10) We posit that while AI holds immense promise to revolutionize embryo selection, its successful integration hinges on demonstrating: (i) robust generalizability across

clinical settings; (ii) proven utility in enhancing live birth rates; and (iii) establishment of a transparent governance framework addressing ethical and regulatory concerns. This review critically appraises the current evidence for AI in embryo selection, explores technical and clinical hurdles, and proposes a pathway for its responsible integration into reproductive medicine.

II. TECHNOLOGICAL FOUNDATIONS OF EMBRYO ASSESSMENT AI

The integration of Artificial Intelligence (AI) into embryo assessment marks a shift from subjective, human-defined criteria to objective, data-driven analysis. This revolution is powered by machine learning (ML), particularly deep learning (DL), which now dominates the field. (11)

A. From Hand-Crafted Features to Automated Representation Learning

Traditional ML relies on hand-crafted features based on established morphological grading systems or key morphokinetic parameters. (12) Algorithms like support vector machines are then trained on these pre-selected datasets. This approach is constrained by human knowledge and bias, potentially missing subtle, complex visual patterns. (13)

In contrast, Deep Learning (DL), specifically Convolutional Neural Networks (CNNs), automates feature extraction. A CNN processes raw pixel data through multiple layers that hierarchically learn increasingly complex features—from simple edges to complex structures like cell boundaries and spatial organization. (14) The model autonomously discovers the most predictive features of developmental potential, often identifying imperceptible patterns. (15)

B. Architectural Foundations: CNNs, RNNs, and Multimodal Integration

Convolutional Neural Networks (CNNs) excel at analyzing static images. Through convolutional layers (feature detection), pooling layers (dimensionality reduction), and fully connected layers (prediction), CNNs learn to correlate visual motifs with outcomes. Studies like kalyani et al. (2024) leveraged CNNs to predict blastocyst formation and implantation, demonstrating superior performance to embryologists. (16)

Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) networks process sequential data like time-lapse videos. Their internal "memory" allows information to persist, learning temporal dependencies between developmental events. This provides a more holistic assessment than any single snapshot. (17)

Multimodal AI represents the cutting edge, integrating diverse data streams to create a comprehensive viability score.

(18) This approach fuses image data with clinical parameters (e.g., maternal age, AMH) and genetic data (e.g., PGT-A results). By learning complex interactions, multimodal AI aims to move from selecting a "good embryo" to the "right embryo for this specific patient." (19) (Table 1)

III. A CRITICAL APPRAISAL OF THE CLINICAL EVIDENCE

The validation of AI for embryo selection has progressed through a hierarchical pathway from feasibility studies to comparative analyses and, finally, prospective trials. (20)

A. Proof-of-Concept and Predictive Accuracy

Foundational work established that DL models can automate grading and identify sub-visual patterns predictive of development. The landmark study by VerMilyea et al. (2020) demonstrated a DL model (Stork®) significantly outperformed embryologists in predicting blastocyst formation and clinical pregnancy. (21) Concurrently, Diakiw et al. (2022) showed a model could predict live birth from a single static blastocyst image, outperforming conventional grading. (22)

B. Comparative Performance: AI vs. Embryologists

Subsequent research directly compared AI-based selection to embryologist selection. Diakiw et al. (2022) expanded AI's scope, demonstrating a model could correlate blastocyst morphology with ploidy status (AUC: 0.68), suggesting a non-invasive correlate to PGT-A. (22) Salih et al. (2022) reported in a systematic review analysis that their AI model's recommendations offered a significant relative increase in implantation potential compared to historical embryologist selections. (23)

C. The Advent of Prospective Randomized Controlled Trials

Prospective RCTs provide the highest level of evidence for clinical efficacy. A pivotal multicenter, double-blinded RCT by Lång et al. (2023) demonstrated non-inferiority of AI selection versus standard morphological assessment for ongoing pregnancy rate. (24) This confirms AI can be safely integrated without compromising outcomes. However, the critical question of superiority in live birth rates remains to be conclusively demonstrated by larger, appropriately powered trials. (25)

IV. IMPLEMENTATION CHALLENGES: FROM BENCH TO BEDSIDE

Translating AI's promising performance into routine clinical practice requires overcoming significant technical and practical hurdles.

A. *The "Black Box" Problem and Explainable AI (XAI)*

The lack of interpretability in complex DL models creates a crisis of confidence for clinicians who must justify embryo selection based on an unexplainable decision. The field is addressing this through Explainable AI (XAI) techniques like Gradient-weighted Class Activation Mapping (Grad-CAM), which generates heatmaps to highlight image regions influential in the model's prediction. (26) XAI is crucial for building trust and may uncover novel biomarkers of viability.

B. *Data Bias and Generalizability*

A model's performance is intrinsically linked to its training data. Significant inter-clinic heterogeneity in patient populations, laboratory protocols, and equipment can cause "model drift," where performance plummets in new environments. (27) External validation on diverse, multi-center datasets is a clinical necessity to ensure robustness and generalizability.

C. *Regulatory Pathways and Workflow Integration*

AI-based tools are classified as Software as a Medical Device (SaMD) by regulatory bodies like the FDA, requiring demonstration of safety, effectiveness, and clinical utility through prospective RCTs. (28) Furthermore, the optimal integration into the embryology lab—as an autonomous selector or a decision-support tool—remains defined. The "human-in-the-loop" model, where AI augments rather than replaces the embryologist, is likely the most prudent path forward, mitigating automation bias and leveraging the strengths of both. (29)

V. FUTURE DIRECTIONS AND ETHICAL CONSIDERATIONS

The integration of AI will fundamentally reshape the embryology laboratory, necessitating evolution in professional roles and ethical frameworks.

A. *The Evolving Role of the Embryologist*

The embryologist will transition from primary scorer to "AI Curator," responsible for overseeing system performance, handling complex edge cases, and integrating AI output with broader clinical context. (23) This evolution demands new training curricula encompassing data literacy and AI fundamentals.

B. *Standardization and Ethical Imperatives*

AI promises unprecedented standardization through objective, quantifiable viability scores, potentially eliminating the subjectivity of current grading systems. However, this raises critical ethical questions regarding:

- **Accountability:** Defining liability between clinicians, embryologists, and software companies in case of error.

- **Equity:** Ensuring high-cost AI tools do not exacerbate healthcare disparities and that algorithms are trained on diverse datasets to prevent biased performance.
- **Data Privacy:** Securing vast repositories of sensitive embryonic images and obtaining explicit patient consent for their use in algorithm training. (30) (Table 2)

VI. CONCLUSION AND FUTURE PERSPECTIVES

Artificial Intelligence has unequivocally transitioned from a speculative technology to a tangible clinical tool in embryology. Its capacity for objective, data-driven assessment marks a paradigm shift from traditional methods. The most impactful future lies in the strategic augmentation of human expertise, creating a collaborative environment where embryologists function as AI-curated decision-makers. (31)

To realize this potential, we issue a call to action for:

1. Large, diverse, multi-center RCTs with live birth primary endpoints to conclusively demonstrate superiority and generalizability.
2. Standardized reporting guidelines for AI studies in ART, mandating transparency in data, methods, and performance metrics.
3. Interdisciplinary collaboration to develop Explainable AI (XAI), establish clear regulatory pathways, and address ethical concerns around equity and privacy.

The collective challenge is to shepherd AI's integration with scientific rigor and ethical foresight, ensuring this powerful technology enhances, rather than replaces, the human expertise central to patient-centered reproductive care. (32) (Table 3)

In conclusion, AI stands as a powerful and inevitable force poised to redefine the standards of embryo selection. Our collective challenge is no longer to prove its technical feasibility, but to shepherd its integration with scientific rigor, ethical foresight, and a unwavering commitment to the principle that technology should enhance, not replace, the human expertise and compassionate care at the heart of patient-centered reproductive medicine. The future of embryology is not algorithmic but augmented, promising a new era of precision and improved outcomes for patients worldwide.

Table 1: Comparative Analysis of Embryo Assessment Methodologies

Feature	Conventional Morphology	Time-Lapse Morphokinetics	AI/Deep Learning
Primary Basis	Static snapshots at specific timepoints	Dynamic, continuous observation	Dynamic, continuous & holistic analysis
Key Parameters	Cell number, symmetry, fragmentation, blastocyst grade	t2, t3, tB, cc2, s2 (standard morphokinetic timings)	Automatically extracted complex features (textures, patterns, temporal relationships)
Subjectivity	High (inter- and intra-observer variability)	Moderate (subjective annotation of timings)	Low (fully automated, objective scoring)
Primary Output	Categorical grade (e.g., "4AA", "Fair")	Categorical grade or semi-quantitative score (e.g., KIDScore)	Continuous, quantitative viability score (e.g., 0.92 probability of blastulation)
Data Integration	Limited to visual morphology	Limited to morphokinetics and morphology	Multimodal potential (images, kinetics, clinical data, genetics)
Key Limitation	Static, subjective, low predictive ceiling	Dependent on manual annotation, debated added value	"Black box" nature, data bias, requires extensive validation

Table 2: Roadmap for Clinical Implementation: Challenges and Required Actions

Domain	Specific Challenge	Recommended Action & Future Direction
Technical Validation & Generalizability	<ul style="list-style-type: none"> "Black box" problem undermines trust. Performance drops due to data bias (patient population, lab protocols, equipment). 	<ul style="list-style-type: none"> Mandate Explainable AI (XAI) techniques (e.g., Grad-CAM) in all clinical systems. Require external validation on multi-center, diverse datasets as a prerequisite for clinical use.
Clinical Evidence & Regulation	<ul style="list-style-type: none"> Level of evidence varies; need for RCTs with LBR endpoints. Regulatory pathway for SaMD is complex, especially for adaptive algorithms. 	<ul style="list-style-type: none"> Conduct large, multi-center RCTs with live birth as the primary endpoint to prove superiority. Develop novel regulatory frameworks for "locked" vs. "adaptive" AI models in collaboration with agencies (FDA, EMA).
Workflow Integration & Expertise	<ul style="list-style-type: none"> Unclear role: autonomous selector vs. decision-support tool. Risk of automation 	<ul style="list-style-type: none"> Adopt a "human-in-the-loop" decision-support model initially. Redefine embryologist

	bias. • Embryologist skill set gap.	training to include data literacy, AI oversight, and curation skills.
Ethics & Equity	• Ambiguity in accountability and liability. • High cost may limit access and exacerbate disparities. • Privacy concerns over embryonic image data.	• Establish clear legal and ethical guidelines on liability (clinician vs. company). • Fund research on cost-effectiveness and develop equitable access models. • Implement granular patient consent and robust data security protocols.

Table 3: Glossary of Key AI Terminology for the Reproductive Medicine Specialist

Term	Definition	Relevance to Embryology
Artificial Intelligence (AI)	A broad field of computer science focused on creating machines capable of performing tasks that typically require human intelligence.	The overarching domain encompassing all automated embryo assessment tools.
Machine Learning (ML)	A subset of AI that uses algorithms to parse data, learn from it, and make a determination or prediction.	The core methodology behind most modern embryo selection algorithms.
Deep Learning (DL)	A subset of ML that uses multi-layered neural networks to learn from vast amounts of data.	The specific, powerful technique that allows algorithms to learn features directly from embryo images without human instruction.
Convolutional Neural Network (CNN)	A class of deep neural networks most commonly applied to analyzing visual imagery.	The standard "engine" for analyzing static embryo images (Day 3, blastocyst).
Recurrent Neural Network (RNN/LSTM)	A class of neural networks designed for sequential data, where context from previous inputs is important.	The ideal architecture for analyzing time-lapse videos , as it can learn from the embryo's entire developmental history.
Explainable AI (XAI)	Methods and techniques that make the output of AI models understandable to humans.	Crucial for building clinical trust ; techniques like heatmaps show which parts of an embryo the AI used for its decision.

ACKNOWLEDGMENT

The author extends her sincere gratitude to the editors and peer reviewers for their invaluable insights and constructive feedback, which significantly enhanced the quality and clarity of this manuscript. We also thank our colleagues in the fields

of reproductive medicine and computer science for their ongoing dialogue and collaboration, which continues to push the boundaries of this interdisciplinary field.

REFERENCES

- [1] Reimundo P, Gutiérrez Romero JM, Rodríguez Pérez T, Veiga E. Single-embryo transfer: a key strategy to reduce the risk for multiple pregnancy in assisted human reproduction. *Adv Lab Med*. 2021;2(2):179-98.
- [2] Sciorio R, Tramontano L, Gullo G. Use of time-lapse technology and artificial intelligence in the embryology laboratory: an updated review. *JBRA Assist Reprod*. 2025;29(2):338-50.
- [3] Nicolielo M, Jacobs CK, Lourenço B, Maffei MC, Chéles DS, Duarte MB, et al. MAIA platform for routine clinical testing: an artificial intelligence embryo selection tool developed to assist embryologists. *Scientific Reports*. 2025;15(1):32273.
- [4] Storr A, Venetis CA, Cooke S, Susetio D, Kilani S, Ledger W. Morphokinetic parameters using time-lapse technology and day 5 embryo quality: a prospective cohort study. *J Assist Reprod Genet*. 2015;32(7):1151-60.
- [5] Siristatidis C, Komitopoulou MA, Makris A, Sialakouma A, Botzaki M, Mastorakos G, et al. Morphokinetic parameters of early embryo development via time lapse monitoring and their effect on embryo selection and ICSI outcomes: a prospective cohort study. *J Assist Reprod Genet*. 2015;32(4):563-70.
- [6] Wu S, Wang X, Liu Y, Ren Y, Zhao M, Song H, et al. Predictive models for live birth outcomes following fresh embryo transfer in assisted reproductive technologies using machine learning. *J Transl Med*. 2025;23(1):1004.
- [7] AlSaad R, Abusarhan L, Odeh N, Abd-Alrazaq A, Choucair F, Zegour R, et al. Deep learning applications for human embryo assessment using time-lapse imaging: scoping review. *Front Reprod Health*. 2025;7:1549642.
- [8] Chen K, Zuo J, Han W, Guo J-h. Intelligent assisted reproduction: Innovative applications of artificial intelligence in embryo health assessment. *LabMed Discovery*. 2025;2(2):100075.
- [9] Rashidi B, Zohori K, Aminzadeh SS, Abachi SF, Behzad F, Omranzadeh A. Challenges of Artificial Intelligence in Cancer Diagnosis: An Update on Future and Prospects. *Razavi Journal of Medicine*. 2025;13(4):1-16.
- [10] Mu F, Cai Z, Du L, Zeng X, Zhou Q, Chen Y, et al. Efficacy and safety of recombinant human granulocyte colony-stimulating factor in patients with unexplained recurrent pregnancy loss: a protocol for a multicenter, randomized, double-blind, controlled trial. *Trials*. 2025;26(1):245.
- [11] Kakkar P, Gupta S, Paschopoulos KI, Paschopoulos I, Paschopoulos I, Siafaka V, et al. The integration of artificial intelligence in assisted reproduction: a comprehensive review. *Front Reprod Health*. 2025;7:1520919.
- [12] Boucret L, Chabrun F, Bogenet M, Reynier P, Bouet P-E, May-Panloup P. Deep-learning model for embryo selection using time-lapse imaging of matched high-quality embryos. *Scientific Reports*. 2025;15(1):28068.
- [13] Barbierato E, Gatti A. The challenges of machine learning: A critical review. *Electronics*. 2024;13(2):416.
- [14] Rayed ME, Islam SMS, Niha SI, Jim JR, Kabir MM, Mridha MF. Deep learning for medical image segmentation: State-of-the-art advancements and challenges. *Informatics in Medicine Unlocked*. 2024;47:101504.
- [15] Vargas-Santiago M, León-Velasco DA, Maldonado-Sifuentes CE, Chanona-Hernandez L. A State-of-the-Art Review of Artificial Intelligence (AI) Applications in Healthcare: Advances in Diabetes, Cancer, Epidemiology, and Mortality Prediction. *Computers*. 2025;14(4):143.
- [16] Kalyani K, Deshpande PS. A deep learning model for predicting blastocyst formation from cleavage-stage human embryos using time-lapse images. *Sci Rep*. 2024;14(1):28019.
- [17] Luong TM, Le NQK. Artificial intelligence in time-lapse system: advances, applications, and future perspectives in reproductive medicine. *J Assist Reprod Genet*. 2024;41(2):239-52.
- [18] Demrozi F, Farmanbar M, Engan K. Multimodal AI (MMAI) for Next-Generation Healthcare: Data Domains, Algorithms, Challenges, and Future Perspectives. *Current Opinion in Biomedical Engineering*. 2025:100632.
- [19] Gao Y, Yuan Y, Wang K, Wang Y, Gao T, Yang Y, et al. Current progress and open challenges for applying artificial intelligence across the in vitro fertilization cycle. *Patterns*. 2025;6(11):101347.
- [20] Wang G, Wang K, Gao Y, Chen L, Gao T, Ma Y, et al. A generalized AI system for human embryo selection covering the entire IVF cycle via multi-modal contrastive learning. *Patterns (N Y)*. 2024;5(7):100985.
- [21] VerMilyea M, Hall JMM, Diakiw SM, Johnston A, Nguyen T, Perugini D, et al. Development of an artificial intelligence-based assessment model for prediction of embryo viability using static images captured by optical light microscopy during IVF. *Hum Reprod*. 2020;35(4):770-84.
- [22] Diakiw SM, Hall JMM, VerMilyea MD, Amin J, Aizpurua J, Giardini L, et al. Development of an artificial intelligence model for predicting the likelihood of human embryo euploidy based on blastocyst images from multiple imaging systems during IVF. *Hum Reprod*. 2022;37(8):1746-59.
- [23] Salih M, Austin C, Warty RR, Tiktin C, Rolnik DL, Momeni M, et al. Embryo selection through artificial intelligence versus embryologists: a systematic review. *Hum Reprod Open*. 2023;2023(3):hoad031.
- [24] Lång K, Josefsson V, Larsson AM, Larsson S, Högborg C, Sartor H, et al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. *Lancet Oncol*. 2023;24(8):936-44.
- [25] Hanassab S, Abbara A, Yeung AC, Voliotis M, Tsaneva-Atanasova K, Kelsey TW, et al. The prospect of artificial intelligence to personalize assisted reproductive technology. *npj Digital Medicine*. 2024;7(1):55.
- [26] Teng Q, Liu Z, Song Y, Han K, Lu Y. A survey on the interpretability of deep learning in medical diagnosis. *Multimed Syst*. 2022;28(6):2335-55.
- [27] Cabanillas Silva P, Sun H, Rezk M, Roccaro-Waldmeyer DM, Fliegenschmidt J, Hulde N, et al. Longitudinal Model Shifts of Machine Learning-Based Clinical Risk Prediction Models: Evaluation Study of Multiple Use Cases Across Different Hospitals. *Journal of Medical Internet Research*. 2024;26.
- [28] Weissman GE. Evaluation and Regulation of Artificial Intelligence Medical Devices for Clinical Decision Support. *Annu Rev Biomed Data Sci*. 2025;8(1):81-99.
- [29] Hanassab S, Abbara A, Yeung AC, Voliotis M, Tsaneva-Atanasova K, Kelsey TW, et al. The prospect of artificial intelligence to personalize assisted reproductive technology. *NPJ Digit Med*. 2024;7(1):55.
- [30] Nouis SC, Uren V, Jariwala S. Evaluating accountability, transparency, and bias in AI-assisted healthcare decision-making: a qualitative study of healthcare professionals' perspectives in the UK. *BMC Med Ethics*. 2025;26(1):89.
- [31] Faiyazuddin M, Rahman SJQ, Anand G, Siddiqui RK, Mehta R, Khatib MN, et al. The Impact of Artificial Intelligence on Healthcare: A Comprehensive Review of Advancements in Diagnostics, Treatment, and Operational Efficiency. *Health Sci Rep*. 2025;8(1):e70312.
- [32] Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK. Reporting guidelines for clinical trial reports for interventions involving artificial



**17th International Conference on New Findings in
Midwifery, Women, Maternity and Infertility**
GEORGIAN INTERNATIONAL ACADEMY OF SCIENCES AND STUDIES

28 November 2025 -TBILISI GEORGIA

<http://icmwmi.ir>
info@icmwmi.ir

intelligence: the CONSORT-AI extension. Lancet Digit Health.
2020;2(10):e537-e48.